Nächste Seminare:

Stattgefundene Seminare:

Donnerstag, den 09. März 2023, 16 Uhr s.t.

PD Dr. med. Michaela Kuhlen

Schwäbisches Kinderkrebszentrum

Universitätsklinikum Augsburg

"Cancer predisposition in children and adolescents - coincidence or fate?"

Mittwoch, den 16. November 2022, 16:15 Uhr s.t.

PD Dr. Matthias Wirth

Department of Hematology, Oncology and Cancer Immunology

Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin

"Exploiting synthetic lethality to overcome therapy resistance in pancreatic cancer and in multiple myeloma"

Donnerstag, den 26. März 2020, 16 Uhr s.t.

PD Dr. Christine Blattner

Karlsruhe Institute of Technology (KIT)

"Identification of novel regulators of p53 by screening a cDNA library from the teleost Medaka"

Donnerstag, den 20. Februar 2020, 16 Uhr s.t.

Prof. Dr. Wolfgang Sippl

Medicinal Chemistry, Institute of Pharmacy

Martin-Luther Universität Halle-Wittenberg

"Development of small molecule inhibitors and chemical degraders (PROTACs) of histone deacetylases"

Dienstag, den 14. Januar 2020, 16 Uhr s.t.

Prof. Alexander Löwer

Systems Biology of the Stress Response, Technical University Darmstadt

"The guardian on the move: dynamics and function of p53 in single cells"



Mittwoch, den 18. Dezember 2019, 13:00 Uhr s.t.

Dr. Helmut Pospiech

Leibniz Institute for Age Research, Fritz Lipmann Institute (FLI), Jena

"50 Shades of Replication Stress"

Donnerstag, den 28. November 2019, 16:00 Uhr s.t.

PD Dr. Aswin Mangerich

Department of Biology, University of Konstanz

"Molecular mechanisms of PARP1-dependent poly(ADP-ribosyl)ation and its interplay with p53"

Mittwoch, den 13. November 2019, 16:30 Uhr s.t.

Prof. Dr. Matthias Altmeyer

Department of Molecular Mechanisms of Disease, University of Zurich

"Phase separation of 53BP1 determines liquid-like behavior of DNA repair compartments"

Dienstag, den 22.Oktober 2019, 17 Uhr s.t.

Prof. Dr. Frank Lyko

Deutsches Krebsforschungszentrum, Heidelberg

"Non-melanoma skin-cancer: epigenetic subclassification and cell-of-origin identification"

Donnerstag, den 17. Oktober 2019, 17 Uhr s.t.

Prof. Dr. Gerhard Fritz

Heinrich Heine Universität Düsseldorf

"Prevention of adverse effects of anticancer therapeutics by pharmacological Modulation of the DNA damage Response"

Mittwoch, den 16 Oktober 2019, 13 Uhr s.t.

Dr.Matthias Wirth

Charité - Universitätsmedizin Berlin

"Molecularly defined subtype-specific vulnerabilities of pancreatic cancer cells"

Donnerstag, den 11. Juli 2019, 16:00 Uhr s.t.

Dr. Martin Fischer

Leibniz- Institut für Alternsforschung - Fritz-Lipmann-Institut (FLI) e.V. Jena

"P53 employs a novel tumor suppressor to expand its gene regulatory network"

Mittwoch, den 10. Juli 2019, 13:00 Uhr s.t.

Dr. Ulf Beier

Division of Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, USA

"SIRT1 as a regulator of T cell function"

Mittwoch, den 05. Juni 2019, 16:00 Uhr s.t.

Dr. Pierre-Olivier Frappart

Universitätsklinikum Ulm

"Actionable perturbations in the DNA damage response establish synergistic therapeutic routes in ATM-deficient pancreatic cancer"

Donnerstag, den 09. Mai 2019, 16 Uhr s.t.

Prof. Dr. Karsten Rippe

Division of Chromatic Networks

DKFZ Heidelberg

"Linking aberrant chromatic features in chronic lymphocytic leukemia to deregulated transcription factor networks"

Thursday, 25 April 2019, at 4 pm

Prof. Rami Aqeilan

Hadassah Medical School

The Hebrew University of Jerusalem

(Supported by SFB 1361) (Pdf, 139,1 KB)

"Mapping the Breakome of Cancer Cells: What have we learned?"

Freitag, den 15. Februar 2019, 11:00 Uhr s.t.

Dr. Boris Pfander

Max-Planck Institute of Biochemistry, Martinsried, Germany

"The Chromatin Response to double-strand breaks"

Donnerstag, den 29. November 2018, 17:30 Uhr s.t.

Prof. Peter L.J. de Keizer

University Medical Center Utrecht, The Netherlands

"Targeting Cellular Senescence against Aging and Cancer"

Donnerstag, den 22. November 2018, 17:30 Uhr s.t.

Prof. Andreas Mund

University of Copenhagen, Denmark

"Clinical Cancer Proteomics: Mapping Tumor Heterogeneity to Identify Novel Biomarkers"